NAUT - Multiplikator Forward P/S Nautilus Bio
Nautilus Biotechnology is developing a unique tool for ultra-precise protein study, although implementation complexities and funding shortages present serious challenges. This forward price-to-sales chart visualizes these factors, where the value of 727.00 serves as the current metric. Currently, Nautilus Biotechnology relies on the delivery of test systems to research centers while awaiting a full-scale commercial breakthrough.
NAUT (nautilus.bio): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal Nautilus Biotechnology|NAUT - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal Nautilus Bio|NAUT - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku NAUT|NAUT - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Nautilus Biotechnology|Likuiditas cepet nautilus.bio
- data bathi bisnis lan rasio investasi:
NAUT - Penghasilan resik perusahaan|Bathi sing dikarepake Nautilus Biotechnology|NAUT - Rasio rega marang bathi|Rega marang bathi mangsa ngarep Nautilus Bio|NAUT - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA NAUT|NAUT - Bathi operasional sadurunge potongan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Nautilus Biotechnology|NAUT - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan nautilus.bio|NAUT - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Nautilus Biotechnology
- rincian pendapatan lan dodolan:
Analisis kabeh metrik perusahaan:Nautilus Biotechnology Inc NAUT
For proteomics innovator Nautilus Biotechnology (NAUT), market expectations often outpace current financial results due to high R&D costs and the development of its AI platform. By analyzing the forward P/S history, an investor compares market capitalization with expected revenue, which helps determine whether a low multiple indicates undervaluation or signals a systemic business decline within the molecular biology sector.
Pesaing wigati
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|Qiagen NV - Rasio rega marang prakiraan pendapatan|Ionis Pharma - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Repligen Inc. RGEN|Avidity Biosciences (RNA) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep crisprtx.com (CRSP)|Multiplikator forward rega marang pendapatan WGS|RARE (Ultragenyx Pharmaceutical Inc.) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S BEAM|SRPT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S TWST (Twist Bioscience)|TXG - Multiplikator forward rega marang pendapatan|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan STOK (Stoke Therapeutics Inc)|BioLife Corp (BLFS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan WVE|Rasio rega marang prakiraan pendapatan Maze Therapeutics Inc|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep sionnatx.com SION|Rasio rega marang prakiraan pendapatan Prime Medicine (PRME)|Rasio rega marang prakiraan pendapatan TSHA (Taysha Gene Therapies Inc)|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|MeiraGTx Corp (MGTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|REGENXBIO Inc. - Multiplikator Forward P/S|Prakiraan rega marang pendapatan solidbio.com (SLDB)|OCGN (Ocugen) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pacific Biosciences of California, Inc. (PACB)|Rasio rega marang prakiraan pendapatan Benitec|Kapitalisasi marang prakiraan pendapatan DSGN (Design Corp)|Multiplikator Forward P/S RCKT|Multiplikator Forward P/S 4dmoleculartherapeutics.com (FDMT)|Lexeo Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Korro Bio Inc. KRRO|EDIT: Multiplikator forward rega marang pendapatan|Silence Therapeutics Corp - Rasio rega marang pendapatan sing dikarepake|PRQR: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CDXS|Rasio rega marang prakiraan pendapatan Sangamo Therapeutics, Inc.|Kapitalisasi marang prakiraan pendapatan MGX (Metagenomi Inc.)|Multiplikator Forward P/S DTIL|Multiplikator Forward P/S generationbio.com (GBIO)|Rasio rega marang prakiraan pendapatan Boundless Bio, Inc. BOLD|XCUR: Kapitalisasi marang prakiraan pendapatan|Celsion Corporation - Multiplikator Forward P/S|PHIO - Multiplikator Forward P/S|MBIO (mustangbio.com) - Multiplikator forward rega marang pendapatan|TransCode Therapeutics, Inc. (RNAZ) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan BNGO|APDN (adnas.com) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S BLUE|Rasio kapitalisasi marang dodolan sing dikarepake immunoprecise.com|Rasio rega marang prakiraan pendapatan Omega OMGA|Singular Genomics Corp - Rasio rega marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|SYRS - Multiplikator Forward P/S|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|TCON - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan UBX
